ArticleFEBS open bio2021

Sulfasalazine synergistically enhances the inhibitory effects of imatinib against hepatocellular carcinoma (HCC) cells by targeting NFκB, BCR/ABL, and PI3K/AKT signaling pathway-related proteins.

Marium M ShamaaPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.